Dr Velayos and colleagues from California performed a systematic review with metaanalysis.
The team evaluated observational studies on the association between 5- aminosalicylate use and colorectal cancer or dysplasia among patients with ulcerative colitis.
The research team conducted a search of Medline, Embase, Biosis, Web of Science, Cochrane Collaboration, reviewed the literature, and consulted with experts.
The researchers included studies if they clearly defined exposure to 5-aminosalicylates in patients with ulcerative colitis.
|5-Aminosalicylates use was not associated with a lower risk of dysplasia|
|American Journal of Gastroenterology|
The team also included studies that reported colorectal cancer or dysplasia outcomes, that reported relative risks or provided data for their calculations.
Quantitative analysis using a random-effects model was used.
The researchers reported that 9 containing 334 cases of colorectal cancer, 140 cases of dysplasia, and a total of 1932 subjects satisfied all inclusion criteria.
The team found that 5 studies reported colorectal cancer outcomes alone, 2 studies reported separate cancer and dysplasia outcomes.
The researchers reported that 2 studies combined outcomes of colorectal cancer or dysplasia.
All primary estimates were homogenous.
With pooled analysis, the team showed a protective association between use of 5-aminosalicylates and colorectal cancer.
The team also observed a protective association between use of 5-aminosalicylates and a combined endpoint of colorectal cancer/dysplasia.
The researchers found that 5-aminosalicylates use was not associated with a lower risk of dysplasia, although only 2 studies evaluated this outcome.
Dr Velayos' team concluded, “Pooled results of observational studies support a protective association between 5-aminosalicylates and colorectal cancer or a combined endpoint of colorectal cancer/dysplasia in patients with ulcerative colitis.”
“Additional studies analyzing the effect of 5-aminosalicylates on risk of dysplasia are needed.”